Basket cover image
16 handpicked stocks

Next-Gen Multiple Myeloma Treatments

Discover biotech companies at the forefront of revolutionary cancer treatments. These carefully selected stocks represent innovators developing cutting-edge immunotherapies for multiple myeloma, a common blood cancer with significant unmet medical needs.

stock
stock
stock
stock
stock
stock
stock
stock
stock
stock

+6

Author avatar

Han Tan | Market Analyst

Updated 2 days ago | Published at Jul 3

About This Group of Stocks

1

Our Expert Thinking

The FDA's approval of new bispecific antibodies for multiple myeloma has created a watershed moment for cancer treatment innovation. This validation opens doors for companies developing similar groundbreaking therapies that can command premium pricing while addressing critical patient needs.

2

What You Need to Know

This collection includes research-intensive biopharmaceutical companies focused on next-generation cancer treatments. These stocks represent a growth-oriented investment in biotechnology innovation, with companies ranging from established pharmaceutical giants to specialized biotech firms.

3

Why These Stocks

Each company was selected based on their direct involvement in developing advanced treatments for multiple myeloma. They're either pioneers who've received recent approvals, direct competitors with similar technologies, or key enablers of bispecific antibody and CAR-T therapies.

Top Picks from This Group

Here are a few of the assets in this group. Create an account to unlock the full list.

REGN

Regeneron Pharmaceuticals, Inc.

REGN

Current price

$540.66

The catalyst company whose FDA approval for its bispecific antibody Lynozyfic validates the market for advanced multiple myeloma therapies.

JNJ

Johnson & Johnson

JNJ

Current price

$155.86

A direct competitor with two approved multiple myeloma treatments: Tecvayli, a BCMA-targeted bispecific antibody, and Carvykti, a leading CAR-T therap...

A direct competitor with two approved multiple myeloma treatments: Tecvayli, a BCMA-targeted bispecific antibody, and Carvykti, a leading CAR-T therapy.

PFE

Pfizer Inc.

PFE

Current price

$25.45

A key competitor with its approved BCMAxCD3 bispecific antibody, Elrexfio, for patients with relapsed or refractory multiple myeloma.

12 Month Growth Potential

Use the growth calculator to see how much investing in these assets could return over one year.

If you invested across these assets:

in 12 months it could be worth:

$1,000.00

+142.57%

Group Performance Snapshot

142.57%

Average 12 Month Profit

On average, analysts expect assets in this group to grow 142.57% over the next year.

11 of 16

Stocks Rated Buy by Analysts

11 of 16 assets in this group are rated Buy by professional analysts.

0.8%

Group Growth

This group averaged a 0.8% return last month.

Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.

Why You'll Want to Watch These Stocks

💊

Breakthrough Cancer Treatments

These companies are developing therapies that could transform survival rates for blood cancer patients. Recent FDA approvals validate both the technology and massive market potential.

💰

Premium Pricing Power

Advanced cancer treatments command high prices due to their life-extending benefits. Companies with approved therapies for late-stage cancers can generate substantial revenue even with relatively small patient populations.

🔬

Scientific Innovation Leaders

This group includes pioneers in immunotherapy technologies that go beyond traditional treatments. Their innovations could potentially expand to other cancer types, multiplying their market opportunities.

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Unlock all the stocks in this group on Nemo

Sign up free to view all stocks in this group and never miss out on another investment opportunity with Nemo.

Sign up in 60 seconds

🆓

Zero commission trading

🛡️

SIPC-protected up to $500,000

🔒

Backed by Exinity Group

🚀

6% AER interest on uninvested cash, paid out daily

AI investment insights

Download the App

Download the Nemo app to view the other stocks in this group.

Nemo Money: Stocks Trading

4.9 rating

Unlock all stocks on Nemo FREE

Frequently Asked Questions

Everything you need to know about the product and billing.

See the full stock group

Download Nemo to see all stocks in this group